Search results

Altasciences eyes early development space, CDMO addition 26-Feb-2019 By Melissa Fassbender Consolidating its businesses under one brand, Altasciences is transitioning to an early drug development CRO – and looking to add a CDMO to manufacture drugs up to Phase II volumes. HTTPS://WWW.OUTSOURCING-PHARMA.COM/ARTICLE/2019/02/26/ALTASCIENCES-EYES-EARLY-DEVELOPMENT-SPACE-CDMO-ADDITION 

Altasciences, a mid-size CRO specializing in a flexible, innovative approach to providing comprehensive early stage drug development, including preclinical, clinical, bioanalysis, and research services, has unveiled a new brand identity and website.

10103 Metcalf Avenue <br> Overland Park, KS 66212 <br> U.S.A. <br>

Altasciences' new brand identity revealed

1200 Beaumont Avenue <br> Montréal, QC H3P 3P1 <br> Canada <br>

575 Armand-Frappier Blvd. <br> Laval, QC H7V 4B3 <br> Canada <br>